[Featured Stock] SK Biopharm, 5th Consecutive Day of Gains... Continuous Record Highs

SK Biopharm has continued its upward trend for five consecutive days, repeatedly hitting new 52-week highs.

As of 9:22 a.m. on the 15th, SK Biopharm is trading at 122,000 KRW, up 2,800 KRW (2.35%) from the previous day. During the session, it rose to 122,500 KRW, setting a new 52-week high again within a single day.

The growth expectations for the epilepsy treatment drug Xcopri appear to be driving the stock price increase. On this day, Meritz Securities raised SK Biopharm's target price from 120,000 KRW to 130,000 KRW, considering the sales growth of Xcopri. The investment rating was maintained at 'Buy.' Junyoung Kim, a researcher at Meritz Securities, explained, "Xcopri is currently maintaining strong growth and maximizing leverage effects based on low cost ratios. We expect the results of Phase 3 clinical trials for partial seizures (PGTC) and patients aged 2 to 17 to be confirmed by 2025 at the latest, and the growth trend will continue by securing the patient population."

SK Biopharm's third-quarter performance this year is expected to meet market expectations. Researcher Kim said, "SK Biopharm's consolidated sales for the third quarter are expected to be 134.3 billion KRW, a 48.6% increase compared to the same period last year, and operating profit is expected to turn positive at 20.2 billion KRW, meeting consensus (average securities firm forecasts). Based on the high growth of Xcopri sales and favorable dollar exchange rates, third-quarter Xcopri sales are expected to increase by 51.1% year-on-year to 118.7 billion KRW."